Following the EGM on the shareholder vote for AorTech’s acquisition of RUA Medical, we have taken the opportunity to review the new expanded management team and the sensitivities around our valuation. The latter remains unchanged despite the recent market turmoil as the key valuation drivers remain acquisitions of the vascular and heart valve products which are based on historical transactions.
31 Mar 2020
RUA Medical now a done deal
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
RUA Medical now a done deal
RUA Life Sciences Plc (RUA:LON) | 8.8 0 (-3.3%) | Mkt Cap: 5.49m
- Published:
31 Mar 2020 -
Author:
Andy Smith -
Pages:
9
Following the EGM on the shareholder vote for AorTech’s acquisition of RUA Medical, we have taken the opportunity to review the new expanded management team and the sensitivities around our valuation. The latter remains unchanged despite the recent market turmoil as the key valuation drivers remain acquisitions of the vascular and heart valve products which are based on historical transactions.